Buy Harte-Hanks (HHS) and TARO Pharmaceuticals (TARO)

By Jim Fink • December 15, 2014

In the November issue of Roadrunner Stocks, two new BUY recommendations and two SELL recommendations have been issued.

1. The Value Portfolio is adding marketing technology services company Harte-Hanks (HHS) and selling auto-equipment supplier Lydall (LDL).

2. The Momentum Portfolio is adding generic skin drug maker TARO Pharmaceuticals (TARO) and selling oil and natural gas producer Matador Resources (MTDR).

Read More . . .

Stock Talk

Comments

Comments Guidelines

Add New Comments

You must be logged in to post to Stock Talk OR create an account

About The Author

Jim Fink

Bio | Archive

Jim Fink is chief investment strategist for Options for Income, Velocity Trader, and Jim Fink's Inner Circle. He has traded options for more than 30 years and generated personal profits of more than $5 million. Jim also serves as an investment analyst at Investing Daily’s flagship investing publication, Personal Finance.

Hopelessly overeducated, Jim holds a bachelor's degree from Yale University, a master's degree from Harvard's Kennedy School of Government, a law degree from Columbia University, and an MBA from the University of Virginia's Darden School of Business. For good measure, he has been a member of the Illinois and D.C. bars.

Prior to joining Investing Daily, and when not incurring student loans hiding out in academe, Jim practiced telecommunications regulatory law for nine years until he realized that he made more money trading stock options than writing briefs. After attending business school, Jim switched gears to the investment realm full-time, working for a university endowment, a private wealth management firm, an insurance and financial planning company, and as a Senior Analyst for an online investment newsletter service that encourages the wearing of funny hats.

A possible but unlikely descendant of legendary brawler and boatman Mike Fink, Jim defies his heritage, believing that investing success requires patience and analysis, not swashbuckling bravado. Besides his passion for analyzing and writing about stocks, Jim likes to hike in the desert Southwest, vacation in Las Vegas, play tennis, and feed his toddler son Cheerios.